Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer

AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies  in patients with colorectal cancer in combination with Ezabenlimab (BI 754091). This advancement  is a result of several years of close and strong collaboration between the teams, which have recently also published their joint research in Nature Communications and Cancers.